News

Suven Life Sciences announced that the 37th Annual General Meeting(AGM) of the company will be held on 25 August 2026.

Net Loss of Suven Life Sciences reported to Rs 45.60 crore in the quarter ended March 2026 as against net loss of Rs 43.94 crore during the previous quarter ended March 2025. Sales rose 3.40% to Rs 1.52 crore in the quarter ended March 2026 as against Rs 1.47 crore during the previous quarter ended March 2025.For the full year,net loss reported to Rs 276.34 crore in the year ended March 2026 as against net loss of Rs 160.75 crore during the previous year ended March 2025. Sales rose 6.76% to Rs 7.11 crore in the year ended March 2026 as against Rs 6.66 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales1.521.47 3 7.116.66 7 OPM %-3331.58-2980.95 --4001.41-2489.19 - PBDT-44.01-42.60 -3 -270.73-154.92 -75 PBT-45.60-43.94 -4 -276.34-160.75 -72 NP-45.60-43.94 -4 -276.34-160.75 -72 Powered by Capital Market - Live News

Suven Life Sciences will hold a meeting of the Board of Directors of the Company on 13 May 2026.

Suven Life Sciences has allotted 3,17,68,764 equity shares of Re 1 each on conversion of warrants. Post allotment, the paid up equity share capital has increased to 2637,20,583 equity shares of Re 1 each. Powered by Capital Market - Live News

Suven Life Sciences has allotted 44,77,612 equity shares on preferential basis up on conversion of equivalent number of convertible warrants. Consequently, the paid up equity share capital has increased to 23,19,51,819 equity shares of Re 1 each. Powered by Capital Market - Live News